1,044 results on '"Tateishi, Ryosuke"'
Search Results
2. The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL)
3. Skeletal muscle status and survival among patients with advanced biliary tract cancer
4. Development of a transformer model for predicting the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation
5. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus
6. Contributors
7. Hepatic functional deterioration in chronic liver disease
8. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
9. Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis
10. Treatment and outcome of hepatorenal syndrome in Japan: a retrospective cohort study using a national inpatient database
11. Increased expression of TNFRSF14 and LIGHT in biliary epithelial cells of patients with primary sclerosing cholangitis
12. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
13. Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals
14. Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors
15. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)
16. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study
17. SAT-470 The risk of hepatic decompensation in patients after the treatment for steatotic liver disease-related hepatocellular carcinoma
18. THU-413 Baseline gamma-glutamyl transpeptidase levels are associated with aggravation of esophagogastric varix after direct-acting antiviral therapy in cirrhotic patients with hepatitis C virus
19. TOP-505 Identification of biomarkers for the treatment efficacy of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, based on chemokine alterations during treatment
20. Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts
21. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis
22. Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data
23. Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
24. Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan.
25. Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021.
26. Machine Learning–Based Personalized Prediction of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation
27. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease
28. Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome (ePRO) monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors
29. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
30. Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells
31. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis
32. Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy: A Case-Control Analysis of over 10,000 Treatments
33. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma
34. Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
35. Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy
36. Prognosis prediction or treatment allocation?
37. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study
38. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
39. Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis
40. Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma
41. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients
42. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
43. Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature
44. Evaluation of comprehensive geriatric assessment for older adults with pancreaticobiliary cancers: A retrospective observational study
45. A Novel Non-invasive Method for Predicting Liver Fibrosis by Quantifying the Hepatic Vein Waveform
46. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy
47. Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis
48. Impact of nucleos(t)ide analogues on the risk of hepatocellular carcinoma in chronic hepatitis B patients: A time-dependent Cox regression analysis.
49. Diagnostic Performance of Two-Dimensional Shear-Wave Elastography and Attenuation Imaging for Fibrosis and Steatosis Assessment in Chronic Liver Disease
50. Development of a transformer model for predicting the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.